Clinical Trial Update: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating somatostatin analogs versus no treatment for non-functioning pancreatic neuroendocrine tumors in MEN1.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumors in Men1

Drugs mentioned

• Somatostatin analogs (somatostatin analogs)

Snippet

Sponsor: Medical University of Vienna | Conditions: Pancreatic Neuroendocrine Tumors in MEN1 | Phase 3 | Status: UNKNOWN